mhurhangee/ep-ind-claims huggingface dataset:
A heat-absorbing soda lime silica glass plate containing iron, tin, selenium, cobalt and sulfur, wherein the mass ratio of divalent iron as calculated as Fe 2 O 3 to total iron as calculated as Fe 2 O 3 is at least 55%, as represented by mass% based on oxides total iron as calculated as Fe 2 O 3: 0.01 to 1.0%, total tin as calculated as SnO 2: 0.02 to 0.3%, Se: 0.0003 to 0.0020%, CoO: 0.0010 to 0.0060%, and total sulfur as calculated as SO 3: 0.001 to 0.1%, the ratio Tv/Te of the visible light transmittance Tv (by illuminant A, 2° visual field) as defined in JIS R3106 calculated as 4 mm thickness of the glass plate to the solar transmittance Te as defined in JIS R3106 calculated as 4 mm thickness of the glass plate, is at least 1.5, the visible light transmittance Tv (by illuminant A, 2° visual field) is at most 65% as defined in JIS R3106 calculated as 4 mm thickness of the glass plate, the excitation purity Pe is at most 7% as defined in JIS Z8701 calculated as 4 mm thickness of the glass plate, the dominant wavelength Dw of the transmitted light calculated as 4 mm thickness of the glass plate, as defined in JIS Z8701, is at most 510 nm, and the ratio of SnO 2 /SO 3 to Fe-redox ((SnO 2 /SO 3)/Fe-redox) is at least 0.20.
A method for forming an array of receptors for microorganisms, comprising: patterning an array of structures on a first substrate to form a template on a surface of the first substrate; applying a receptor material to a face of a second substrate; contacting the face of the second substrate with the template to remove a portion of the receptor material from the second substrate, thereby forming an array of receptors on the second substrate, the method further comprising: contacting a target substrate with the array of receptors to transfer the array of receptors to the target substrate, and contacting the target substrate with a solution comprising the microorganisms to transfer a portion of the microorganisms to the array of receptors. patterning an array of structures on a first substrate to form a template on a surface of the first substrate; applying a receptor material to a face of a second substrate; contacting the face of the second substrate with the template to remove a portion of the receptor material from the second substrate, thereby forming an array of receptors on the second substrate, the method further comprising: contacting a target substrate with the array of receptors to transfer the array of receptors to the target substrate, and contacting the target substrate with a solution comprising the microorganisms to transfer a portion of the microorganisms to the array of receptors. contacting a target substrate with the array of receptors to transfer the array of receptors to the target substrate, and contacting the target substrate with a solution comprising the microorganisms to transfer a portion of the microorganisms to the array of receptors.
A tissue repair structure for use in the treatment of any tissue defect or to regenerate any tissue in vivo, comprising a) a cell-free collagen membrane and b) stem cells adhered to a surface of said membrane, wherein the surface is porous such that the stem cells can migrate into the membrane and into the tissue. a) a cell-free collagen membrane and b) stem cells adhered to a surface of said membrane,
Layer arrangement having: - a carrier layer which is constructed to be able to be deep-drawn and which has an upper side and a lower side; - a covering layer which is constructed to be able to be deep-drawn and which has an upper side and a lower side, wherein the covering layer extends substantially over the entire upper side and/or lower side of the carrier layer, there is arranged between the carrier layer and the covering layer at least one separation layer which extends substantially over the entire face between the carrier layer and the covering layer, wherein the carrier layer can be separated with respect to the covering layer in the region of the separation layer with a first peeling force of from 0.5 to 6N/15 mm, measured with a T-peel test, 90° (DIN 55529), characterised in that the separation layer is constructed to be able to be deep-drawn and comprises materials which have at least one binder selected from a group comprising first additives, wherein the first additives are nitrocellulose, carboxymethylcellulose and starch and/or at least one derivative from the above-mentioned materials, and at least one separation agent selected from a group comprising second additives with a melting temperature of from 40 to 250°C, in particular inorganic additives, such as silicone and/or natural, synthetic and/or partially synthetic highly viscous waxes or wax-like substances and/or at least one derivative from the above-mentioned materials. - a carrier layer which is constructed to be able to be deep-drawn and which has an upper side and a lower side; - a covering layer which is constructed to be able to be deep-drawn and which has an upper side and a lower side, wherein the covering layer extends substantially over the entire upper side and/or lower side of the carrier layer, there is arranged between the carrier layer and the covering layer at least one separation layer which extends substantially over the entire face between the carrier layer and the covering layer, wherein the carrier layer can be separated with respect to the covering layer in the region of the separation layer with a first peeling force of from 0.5 to 6N/15 mm, measured with a T-peel test, 90° (DIN 55529), characterised in that the separation layer is constructed to be able to be deep-drawn and comprises materials which have at least one binder selected from a group comprising first additives, wherein the first additives are nitrocellulose, carboxymethylcellulose and starch and/or at least one derivative from the above-mentioned materials, and at least one separation agent selected from a group comprising second additives with a melting temperature of from 40 to 250°C, in particular inorganic additives, such as silicone and/or natural, synthetic and/or partially synthetic highly viscous waxes or wax-like substances and/or at least one derivative from the above-mentioned materials.
Use of gene expression profiles obtained in vitro from patient samples for differentiating between the non-infectious and infectious causes of multiple organ failure, the gene expression profiles being obtainable from a method for in vitro measurement of gene expression profiles, wherein: a. the patient's gene expression of a plurality of specific genes related to non-infectious and infectious causes of multiple organ failure is determined in a patient's sample, and b. the genes and/or gene fragments specific for differentiating non-infectious and infectious causes of multiple organ failure are selected from a group consisting of: sequence ID No. 1 to sequence ID No. 1297 as well as gene fragments thereof with at least 20-200 nucleotides, and c. the genes and/or gene fragments selected from the group consisting of sequence ID No.1 to 721 show significantly elevated expression values of patients with infectious MOF when compared to the patients with non-infectious MOF and/or genes and/or gene fragments selected from the group consisting of sequence ID No. 722 to 1297 show significantly decreased expression values of patients with infectious MOF when compared to the patients with non-infectious MOF. a. the patient's gene expression of a plurality of specific genes related to non-infectious and infectious causes of multiple organ failure is determined in a patient's sample, and b. the genes and/or gene fragments specific for differentiating non-infectious and infectious causes of multiple organ failure are selected from a group consisting of: sequence ID No. 1 to sequence ID No. 1297 as well as gene fragments thereof with at least 20-200 nucleotides, and c. the genes and/or gene fragments selected from the group consisting of sequence ID No.1 to 721 show significantly elevated expression values of patients with infectious MOF when compared to the patients with non-infectious MOF and/or genes and/or gene fragments selected from the group consisting of sequence ID No. 722 to 1297 show significantly decreased expression values of patients with infectious MOF when compared to the patients with non-infectious MOF.
A method for performing quantum logic operations in a quantum computation device comprising a pair of donor atoms incorporated in crystalline silicon, each donor atom having a nucleus and at least one bound electron in which the logic operations are performed between two electron spins by controlling exchange oscillations between a pair of electron spin states; quantum information is encoded in a spin state of the bound electron of each donor atom of the pair of donor atoms, and the spin state of the nucleus of each donor atom is coupled to the spin state of its respective bound electron via the hyperfine interaction; an exchange interaction between the spin state of each of the two electrons results in exchange oscillations between them; and the method comprises the steps of: - preparing the nuclear spins of the two donors in opposite states; the method characterised in the step of: - tuning the exchange interaction by the application of a variable voltage to selectively change the relative strength of the exchange interaction with respect to the hyperfine interaction; and thereby selectively controlling the exchange oscillations between the two bound electrons such that the quantum logic operations take place while J ≫ A, whereas the quantum logic operations are stopped to allow the readout of the results while J ≪ A. - preparing the nuclear spins of the two donors in opposite states; the method characterised in the step of: - tuning the exchange interaction by the application of a variable voltage to selectively change the relative strength of the exchange interaction with respect to the hyperfine interaction; and thereby selectively controlling the exchange oscillations between the two bound electrons such that the quantum logic operations take place while J ≫ A, whereas the quantum logic operations are stopped to allow the readout of the results while J ≪ A. - tuning the exchange interaction by the application of a variable voltage to selectively change the relative strength of the exchange interaction with respect to the hyperfine interaction; and thereby selectively controlling the exchange oscillations between the two bound electrons such that the quantum logic operations take place while J ≫ A, whereas the quantum logic operations are stopped to allow the readout of the results while J ≪ A.
An assembly comprising: a unitary bidirectional connector having a torque-receiving portion that is radially oriented about a major axis of the unitary bidirectional connector, the torque-receiving portion having a first surface and an opposing second radial surface; the unitary bidirectional connector further having a first threaded shaft and a second threaded shaft, the first threaded shaft projecting outwardly from the first surface, the second threaded shaft projecting outwardly from the second radial surface, the first threaded shaft and the second threaded shaft being aligned such that their respective major axes coincide with the major axis of the unitary bidirectional connector, the first threaded shaft having an axial ground wire slot configured to receive a ground wire therein, the second threaded shaft having a base; characterized in that: the assembly is a wire grounding assembly for use in grounding a photovoltaic module having an anodized aluminum frame; the first surface of the torque-receiving portion is a first radial surface; the unitary bidirectional connector further includes an annular sharp projection that projects beyond a plane of the second radial surface, encircling the base of the second threaded shaft, the annular sharp projection being configured to penetrate a first non-conductive surface of the frame upon application of sufficient torque to the torque-receiving portion; and the wire grounding assembly further includes a nut dimensioned to engage the second threaded shaft, the nut having an attached free-spinning washer, the attached free-spinning washer having a serrated surface configured to penetrate a second non-conductive surface of the frame opposing the first non-conductive surface of the frame. the assembly is a wire grounding assembly for use in grounding a photovoltaic module having an anodized aluminum frame; the first surface of the torque-receiving portion is a first radial surface; the unitary bidirectional connector further includes an annular sharp projection that projects beyond a plane of the second radial surface, encircling the base of the second threaded shaft, the annular sharp projection being configured to penetrate a first non-conductive surface of the frame upon application of sufficient torque to the torque-receiving portion; and the wire grounding assembly further includes a nut dimensioned to engage the second threaded shaft, the nut having an attached free-spinning washer, the attached free-spinning washer having a serrated surface configured to penetrate a second non-conductive surface of the frame opposing the first non-conductive surface of the frame.
A method comprising: receiving, by a wireless device (210, 1502), an activation command indicating activation of a set of at least two transmission configuration indicator, TCI, states for a control resource set, coreset, with a lowest coreset index in an active downlink bandwidth part of a cell; selecting, for transmission of an uplink signal, a TCI state that occurs first in the set of the at least two TCI states in response to the coreset being activated with the at least two TCI states; and transmitting, via an uplink resource, the uplink signal with a transmission parameter determined based on the TCI state. receiving, by a wireless device (210, 1502), an activation command indicating activation of a set of at least two transmission configuration indicator, TCI, states for a control resource set, coreset, with a lowest coreset index in an active downlink bandwidth part of a cell; selecting, for transmission of an uplink signal, a TCI state that occurs first in the set of the at least two TCI states in response to the coreset being activated with the at least two TCI states; and transmitting, via an uplink resource, the uplink signal with a transmission parameter determined based on the TCI state.
An implantable electrical device (100, 101, 102), comprising: a flexible substrate having a first surface and one or more electrical conductors; a first biocompatible encapsulation layer; a first adhesion layer, disposed between the first surface and the first encapsulation layer; wherein: the first surface comprises a Liquid-Crystal Polymer; the first adhesion layer is configured and arranged to conform to the first surface and comprises a ceramic material; the first encapsulation layer comprises a silicone rubber, and the first adhesion layer and the first encapsulation layer are configured and arranged to resist the ingress of fluids from a human or animal body into at least a portion of the first surface. a flexible substrate having a first surface and one or more electrical conductors; a first biocompatible encapsulation layer; a first adhesion layer, disposed between the first surface and the first encapsulation layer; wherein: the first surface comprises a Liquid-Crystal Polymer; the first adhesion layer is configured and arranged to conform to the first surface and comprises a ceramic material; the first encapsulation layer comprises a silicone rubber, and the first adhesion layer and the first encapsulation layer are configured and arranged to resist the ingress of fluids from a human or animal body into at least a portion of the first surface. the first surface comprises a Liquid-Crystal Polymer; the first adhesion layer is configured and arranged to conform to the first surface and comprises a ceramic material; the first encapsulation layer comprises a silicone rubber, and the first adhesion layer and the first encapsulation layer are configured and arranged to resist the ingress of fluids from a human or animal body into at least a portion of the first surface.
Process for welding two polyamide parts comprising a process step wherein a welded joint between the two polyamide parts is made and wherein both polyamide parts consist of a polyamide composition comprising a polyamide polymer and optionally comprising additives, characterized in that at least one of the two polyamide parts consists of a polyamide composition comprising an iron containing additive, and in that the polyamide polymer is a blend of at least two polyamides, a first semicrystalline polyamide having a melting point of at least 260°C and a second polyamide having a melting temperature less than 260°C, or, where the second polyamide is an amorphous polyamide, having a glass transition temperature less than 260°C.
A process for making one or more benzoxazine compound(s) comprising reacting an aromatic amine containing at least one primary amino group with alkyl formcel and at least one phenolic compound, which contains at least one hydrogen at an ortho position relative to -OH group, wherein the alkyl formcel comprises ROCH 2 OH, where R is selected from C1-C12 straight chain, branched chain, acyclic or cyclic, saturated or unsaturated hydrocarbyl group, preferably, R = C1-C4 alkyl group.
A User-terminal for entering secure user information, comprising: - a processor for running an operating system, with applications; - a touch screen for displaying information and receiving user inputs and also to receive the secure information from the user; - a Security-Box being connected between the touch screen and the processor, to control the user input on the touch screen to the processor, - wherein the Security-Box is being configured to run in two modes Secure Mode and Clear Text Mode, - wherein when running in Secure Mode the user input is not forwarded as touch coordinates to the processor and when running in Clear Text Mode the touch coordinates are transmitted to the processors; - wherein the user-terminal is configured to run at least two types of applications displaying information on the touch screen and allowing an interaction with the user, - wherein applications of the first type are interacting with the Security-Box to perform security relevant financial transactions and applications of the second type, Add-on applications, are interacting in Clear Text Mode with the touch screen, characterized in that - the Security-Box is configured to authenticate an application using a cryptographic method with one or more security keys before interacting with said application and allowing switching into the Secure Mode. - a processor for running an operating system, with applications; - a touch screen for displaying information and receiving user inputs and also to receive the secure information from the user; - a Security-Box being connected between the touch screen and the processor, to control the user input on the touch screen to the processor, - wherein the Security-Box is being configured to run in two modes Secure Mode and Clear Text Mode, - wherein when running in Secure Mode the user input is not forwarded as touch coordinates to the processor and when running in Clear Text Mode the touch coordinates are transmitted to the processors; - wherein the user-terminal is configured to run at least two types of applications displaying information on the touch screen and allowing an interaction with the user, - wherein applications of the first type are interacting with the Security-Box to perform security relevant financial transactions and applications of the second type, Add-on applications, are interacting in Clear Text Mode with the touch screen, characterized in that - the Security-Box is configured to authenticate an application using a cryptographic method with one or more security keys before interacting with said application and allowing switching into the Secure Mode.
A compound of the formula: wherein R 1 is aryl or heteroaryl, wherein said aryl and heteroaryl groups are optionally substituted with one to three substituents independently selected from the group consisting of hydroxyl, cyano, halo, C 1-3 alkyl, O(C 1-3 alkyl, NH 2, CH 2 NH 2,(C=O)NH 2 or heteroaryl; R 2 is aryl, heteroaryl, wherein said aryl and heteroaryl groups are optionally substituted with one to three substituents independently selected from the group consisting of hydroxyl, oxo, cyano, halo, C 1-3 alkyl, C 1-3 haloalkyl, O(C 1-3 alkyl) and NH 2; R 3 is hydrogen, C 1-3 alkyl, or C 3-7 cycloalkyl; R 4 is hydrogen or C 1-4 alkyl; R 5 is (a) hydrogen, (b) CH 2 -C 3-6 cycloalkyl; (c) piperidinyl, which is optionally substituted with hydroxyl, oxo, cyano, halo, C 1-3 alkyl, or (d) C 1-4 alkyl which is optionally substituted with NR 6 R 7, N + (CH 3) 3, NH(C=O)R 6, O(C=O)R 6, NR 6 SO 2 R 7, NHSO 2 cyclopropyl or heterocyclyl, wherein said heterocyclyl is optionally substituted with R 6; R 6 is hydrogen or C 1-4 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo and hydroxyl; R 7 is hydrogen or C 1-3 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo and hydroxyl; or a pharmaceutically acceptable salt thereof. wherein R 1 is aryl or heteroaryl, wherein said aryl and heteroaryl groups are optionally substituted with one to three substituents independently selected from the group consisting of hydroxyl, cyano, halo, C 1-3 alkyl, O(C 1-3 alkyl, NH 2, CH 2 NH 2,(C=O)NH 2 or heteroaryl; R 2 is aryl, heteroaryl, wherein said aryl and heteroaryl groups are optionally substituted with one to three substituents independently selected from the group consisting of hydroxyl, oxo, cyano, halo, C 1-3 alkyl, C 1-3 haloalkyl, O(C 1-3 alkyl) and NH 2; R 3 is hydrogen, C 1-3 alkyl, or C 3-7 cycloalkyl; R 4 is hydrogen or C 1-4 alkyl; R 5 is (a) hydrogen, (b) CH 2 -C 3-6 cycloalkyl; (c) piperidinyl, which is optionally substituted with hydroxyl, oxo, cyano, halo, C 1-3 alkyl, or (d) C 1-4 alkyl which is optionally substituted with NR 6 R 7, N + (CH 3) 3, NH(C=O)R 6, O(C=O)R 6, NR 6 SO 2 R 7, NHSO 2 cyclopropyl or heterocyclyl, wherein said heterocyclyl is optionally substituted with R 6; (a) hydrogen, (b) CH 2 -C 3-6 cycloalkyl; (c) piperidinyl, which is optionally substituted with hydroxyl, oxo, cyano, halo, C 1-3 alkyl, or (d) C 1-4 alkyl which is optionally substituted with NR 6 R 7, N + (CH 3) 3, NH(C=O)R 6, O(C=O)R 6, NR 6 SO 2 R 7, NHSO 2 cyclopropyl or heterocyclyl, wherein said heterocyclyl is optionally substituted with R 6; R 6 is hydrogen or C 1-4 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo and hydroxyl; R 7 is hydrogen or C 1-3 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo and hydroxyl; or a pharmaceutically acceptable salt thereof.